{"title":"《柳叶刀-肿瘤》2025年修正；26日:1067 - 80","authors":"","doi":"10.1016/s1470-2045(25)00488-7","DOIUrl":null,"url":null,"abstract":"<em>Hungria V, Robak P, Hus M, et al. Belantamab mafodotin plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): updated overall survival analysis from a global, randomised, open-label, phase 3 trial.</em> Lancet Oncol <em>2025; <strong>26:</strong> 1067–80</em>—In this Article, the affiliation for Prof Marek Hus and Michał Mielink should have been “Medical University of Lublin”. This correction has been made to the online version as of Sept 29, 2025.","PeriodicalId":22865,"journal":{"name":"The Lancet Oncology","volume":"4 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Correction to Lancet Oncol 2025; 26: 1067–80\",\"authors\":\"\",\"doi\":\"10.1016/s1470-2045(25)00488-7\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<em>Hungria V, Robak P, Hus M, et al. Belantamab mafodotin plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): updated overall survival analysis from a global, randomised, open-label, phase 3 trial.</em> Lancet Oncol <em>2025; <strong>26:</strong> 1067–80</em>—In this Article, the affiliation for Prof Marek Hus and Michał Mielink should have been “Medical University of Lublin”. This correction has been made to the online version as of Sept 29, 2025.\",\"PeriodicalId\":22865,\"journal\":{\"name\":\"The Lancet Oncology\",\"volume\":\"4 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-09-29\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The Lancet Oncology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1016/s1470-2045(25)00488-7\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Lancet Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/s1470-2045(25)00488-7","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Hungria V, Robak P, Hus M, et al. Belantamab mafodotin plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): updated overall survival analysis from a global, randomised, open-label, phase 3 trial. Lancet Oncol 2025; 26: 1067–80—In this Article, the affiliation for Prof Marek Hus and Michał Mielink should have been “Medical University of Lublin”. This correction has been made to the online version as of Sept 29, 2025.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
